X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Obgemsa (vibegron) is a beta-3 adrenergic agonist, small molecule, which is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency in adults.
Lead Product(s): Vibegron
Therapeutic Area: Urology Product Name: Obgemsa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2024
Details:
PFL-002/VERT-002 is a mAb developed by Vertical Bio, acting as a degrader of c-MET, in patients with solid tumors, including non-small cell lung cancer with mutations or amplification of MET.
Lead Product(s): PFL-002
Therapeutic Area: Oncology Product Name: VERT-002
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2024
Details:
Atara has entered into a partnership with Pierre Fabre for the U.S. and remaining global commercial markets for Tab-Cel (Tabelecleucel), which is indicated for the treatment of EBV-positive post-transplant lymphoproliferative disease.
Lead Product(s): Tabelecleucel
Therapeutic Area: Immunology Product Name: Tab-cel
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Recipient: Atara Biotherapeutics
Deal Size: $667.0 million Upfront Cash: $27.0 million
Deal Type: Partnership May 20, 2024
Details:
Obgemsa (vibegron) is a beta-3 adrenergic agonist, small molecule drug candidate, which is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults.
Lead Product(s): Vibegron
Therapeutic Area: Urology Product Name: Obgemsa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2024
Details:
Through the agreement, Pierre Fabre will access the development and global commercialization of Exarafenib, an investigational pan-RAF inhibitor, which is being evaluated in preclinical trial studies for the treatment of NRAS-mutated melanoma.
Lead Product(s): Exarafenib
Therapeutic Area: Oncology Product Name: Exarafenib
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Kinnate Biopharma
Deal Size: $30.5 million Upfront Cash: Undisclosed
Deal Type: Agreement March 01, 2024
Details:
The companies will work to seek the regulatory approval for Foundation Medicine assays which detect mutations including BRAFV600E to identify patients for potential treatment with Pierre’s BRAF/MEK inhibitor, BRAFTOVI (encorafenib) and MEKTOVI (binimetinib), in the EU.
Lead Product(s): Encorafenib,Binimetinib
Therapeutic Area: Oncology Product Name: Braftovi
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Foundation Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 15, 2023
Details:
Braftovi (encorafenib) + Mektovi (binimetinib) is approved for the treatment of adult patients with BRAFV600-mutant advanced non-small cell lung cancer (NSCLC), who are either treatment naïve or have received prior therapy.
Lead Product(s): Encorafenib,Binimetinib
Therapeutic Area: Oncology Product Name: Braftovi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2023
Details:
Under the terms of the agreement, Pierre Fabre gains U.S. and remaining global commercial markets for tab-cel (tabelecleucel), an allogeneic Epstein-Barr virus (EBV)-specific T-cell immunotherapy.
Lead Product(s): Tabelecleucel
Therapeutic Area: Infections and Infectious Diseases Product Name: Tab-cel
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Recipient: Atara Biotherapeutics
Deal Size: $640.0 million Upfront Cash: $30.0 million
Deal Type: Partnership November 01, 2023
Details:
STX-721, Scorpion's highly differentiated, orally bioavailable, irreversible highly selective tyrosine kinase inhibitor targeting EGFR and ERBB2 (HER2) Exon 20 insertion mutations, well-known, clinically validated oncogenic drivers in non-small cell lung cancer.
Lead Product(s): STX-721
Therapeutic Area: Oncology Product Name: STX-721
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Scorpion Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2023
Details:
Under the terms of the collaboration, Vernalis will use its expertise to enable drug discovery against an undisclosed portfolio of multiple oncology targets and use fragment and structure-based methods to identify small molecules that modulate their activity.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Recipient: Vernalis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 25, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
